Beauty Health: SkinStylus receives new FDA clearance for facial acne scarring

The Beauty Health Company home to hero brand Hydrafacial announced the U.S. Food and Drug Administration has cleared its SkinStylus microneedling device for use on facial acne scarring in Fitzpatrick skin types I, II, and III in patients aged 22 years and older, making it the only microneedling device FDA cleared for both the face and abdomen. The clearance from the FDA is a notable milestone for SkinStylus(TM) since its acquisition by BeautyHealth in February of this year, revealing of an ambitious and accelerated path for the brand since coming under BeautyHealth’s leadership. “SkinStylus’ new facial indication for acne scarring is a testament to BeautyHealth’s innovation track record, proven brand building expertise, and our commitment to creating the future of skin health,” said BeautyHealth President and Chief Executive Officer Andrew Stanleick. “Our goal is to become the world’s leading beauty, health and wellness platform by bringing together incredible brands and growing them into category leaders. This SkinStylus indication further unlocks the potential of the highly complementary treatments in our multi-brand ecosystem and positions SkinStylus for exponential growth in the years ahead.”